M

MacroGenics, Inc. (MGNX)

NMS – Real vaqt narxi. Valyuta: USD

3.52

+0.57 (19.32%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

M

MacroGenics, Inc. (MGNX)

NMS – Real vaqt narxi. Valyuta: USD

3.52

+0.57 (19.32%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.05.2026

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora

05.05.2026

Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

04.05.2026

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million

08.04.2026

FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4.

12.03.2026

MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

09.03.2026

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.25 per share a year ago.

09.03.2026

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora

04.05.2026

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million

08.04.2026

FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4.

09.03.2026

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline.

Search stocks

MacroGenics, Inc. (MGNX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

MacroGenics, Inc. (MGNX)

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study

MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

Videolar

No Data

Press-relizlar

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures